The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: a systematic review and meta-analysis

In clinical studies, medical oncologists generally group squamous cell carcinomas that originate in the oral cavity, oropharynx, hypopharynx, and larynx as the same disease, head and neck squamous cell carcinoma (HNSCC). The epidermal growth factor receptor (EGFR) is overexpressed in the overwhelming majority of HNSCC, and its overexpression is associated with poor prognosis [1]. Cetuximab, an antibody against EGFR, has been approved in combination with chemotherapy as the first-line treatment for recurrent or metastatic HNSCC [2].

Source: Radiotherapy and Oncology - February 12, 2021 Category: Radiology Authors: Deheng Nie, Xin Wang, Meiting Sun, Zhenbang Feng, Fengli Pei, Wenhui Liu, Zonghan Wang, Fujun Han Tags: Original Article Source Type: research